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Abstract
Acquired long QT interval has been widely reported to be a consequence of drug therapy and
electrolyte disturbances. We describe two cases of multifactorial acquired QT interval prolon-
gation and torsades de pointes. In the first case, the drugs venlafaxine, amiodarone and
domperidone may have contributed to QT interval prolongation in a patient with hypokalemia
and hypomagnesaemia. In the second case, QT interval prolongation occurred in a patient
taking quetiapine and citalopram, and whose use of hydrocholorothiazide and history of chronic
alcohol abuse likely contributed by rendering the patient hypokalemic. These cases highlight the
potential risks associated with polypharmacy and demonstrate that though torsades de pointes
is an uncommon arrhythmia, the combination of multiple factors known to prolong
QT interval may precipitate this life-threatening arrhythmia. (Cardiol J 2010; 17, 2: 184–188)
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Introduction
Long QT (LQT) interval is an electrocardio-
graphy (ECG) manifestation of delayed repolariza-
tion of the heart that can precipitate life-threatening
arrhythmias, such as torsades de pointes (TdP).
Acquired LQT is most commonly a consequence of
drug therapy or electrolyte disturbances. Several
studies have shown a role for polytherapy in caus-
ing prolonged QT intervals, especially when thera-
py includes both an antipsychotic and an additional
antidepressant [1, 2]. Furthermore, electrolyte dis-
turbances, especially hypokalemia, have been
shown to increase the risk of developing cardiac
arrhythmias and of prolonging the QT interval [3].
We describe two cases of QT interval prolon-
gation and TdP occurring as a result of polyphar-
macy with drugs known to prolong QT interval and
in the setting of electrolyte disturbances caused by
diuretics and/or a history of chronic alcohol abuse.
These cases highlight the potential risks associat-
ed with polypharmacy and reveal the multifactorial
nature of QT interval prolongation that may allow
TdP to manifest itself.
Case 1
A 64 year-old obese, Caucasian woman with
a medical history of stable angina, type 2 diabetes
mellitus, hypertension, stroke, atrial fibrillation
(AF), hypothyroidism and mechanical mitral valve
from rheumatic valvular disease, presented to the
Emergency Department (ED) after a motor vehi-
cle accident. She described experiencing a non-pro-
dromal syncopal episode prior to the accident and
reported having had three similar episodes in the
last five years. Her home medications are listed in
Table 1. Notably, she recalls having previously been
on citalopram 40 mg but was switched to venlafax-
ine within the last six months. Her baseline labora-
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tory investigations at the time of presentation to the
ED revealed a serum potassium level of 2.9 mmol/L,
serum magnesium of 0.62 mmol/L, as well as a nor-
mal CBC, glucose, urea, creatinine, corrected cal-
cium, TSH and two sets of cardiac enzymes. An
initial ECG (Fig. 1) demonstrated AF with a ven-
tricular response rate of 65 bpm, and a ‘scooped’
ST-segment with a corrected QT interval (QTc) of
666 ms. The patient was stable, having suffered no
serious injuries from the accident, and was thus ad-
mitted under the orthopaedics service to a ward bed
with telemetry monitoring.
That night, the patient experienced two short
episodes of wide complex tachycardia. She felt diz-
zy with the first, and lost consciousness with the
latter. A bolus of 150 mg of amiodarone was admin-
istered, followed by intravenous infusion. A 12-lead
ECG (Fig. 2) revealed a classic short-long-short
sequence followed by an ‘R on T’ phenomenon ini-
tiating self-terminating, asymptomatic TdP. The
patient was transferred to the Coronary Care Unit
where rapid correction of hypokalemia and hy-
pomagnesaemia was initiated and all medications
known to be associated with QT interval prolonga-
tion were discontinued. A temporary transvenous
pacemaker was inserted with the aim of increasing
the heart rate (HR) to 120 bpm. Over the subse-
quent twenty-four hours, the patient’s QTc normal-
ized and she was discharged home with no recur-
rent episodes of TdP.
Case 2
A 58 year-old woman with a history of chronic
alcohol abuse presented to a peripheral hospital ED
complaining of weakness, nausea, diaphoresis and
malaise. She suffered no chest discomfort or light-
headedness. She reportedly had not consumed any
alcohol in the previous three days. Her medical his-
tory was significant for congestive heart failure,
chronic obstructive pulmonary disease, obstructive
sleep apnea, and hypertension. Her regular medica-
tions are listed in Table 1. Initial laboratory investi-
gations revealed serum potassium of 2.5 mmol/L
and serum magnesium of 0.75 mmol/L. A 12-lead
ECG (Fig. 3A) showed a prolonged QTc of 720 ms.
TdP was documented in an ECG strip that is not of
sufficient quality to be published. A transfer to our
tertiary care hospital was initiated. En-route, she
experienced three episodes of ventricular fibrilla-
Table 1. List of medications prior to admission.
Case 1 Case 2
Irbesartan Quetiapine 50 mg TID
150 mg BID and 200 mg QHS
Digoxin 0.25 mg OD Citalopram 60 mg OD
Furosemide 40 mg OD Hydrochlorotiazide
25 mg OD
Metalazone 2.5 mg OD Clonazepam 1 mg TID
Metformin 1000 mg BID Acamprosate 333 mg
TID
Glyburide 5 mg BID Atenolol 25 mg BID
Venlafaxine 112.5 mg OD Ranitidine 150 mg OD
Levothyroxine Mirtazipine 30 mg QHS
200 mg OD
Omeprazole 20 mg OD Rosuvastatin 10 mg OD
Lipitor 10 mg OD
Domperidone 10 mg TID
Figure 1. Case 1: electrocardiogram at admission. QTc: 666 ms.
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tion requiring numerous defibrillations. On arrival,
the patient was treated with intravenous magnesi-
um sulphate and metoprolol, a temporary trans-
venous pacemaker to increase the HR to 120 bpm,
and all medications known to be associated with
a prolonged QT interval were discontinued. Subse-
quent ECGs demonstrated correction of the QTc
interval and, ultimately, the patient was discharged
home without recurrence of arrhythmias. At follow-
up, her measured QTc was still in the normal range
at 410 ms (Fig. 3B).
Discussion
These two cases illustrate the medical impor-
tance of multifactorial QT interval prolongation.
Acquired LQT interval is most commonly a conse-
quence of drug therapy or electrolyte disturbanc-
es.  Also, some patients have a ‘forme fruste’ of
congenital LQT syndrome, in which a mutation or
polymorphism in one of the LQT syndrome genes
is clinically unapparent until the patient is exposed
to a particular drug [4].
The means by which drugs prolong the QT in-
terval is typically linked to the blockade of rapidly
activating delayed rectifier (repolarizing) potassi-
um currents (IKr). This not only results in reduction
of the repolarizing currents and consequent prolon-
gation of the QT interval, but also the development
of early afterdepolarizations and re-entry pheno-
mena [5]. However, although an increase in the QT
interval favours the occurrence of TdP, it seems as
though this arrhythmia often requires potentiation
by certain risk factors for TdP to become manifest.
Notably, female gender has been identified as one
of the most commonly involved risk factors, along
with heart disease and hypokalemia in the setting
of polypharmacy [6]. Additionally, co-administration
of certain drugs known to affect metabolism, pro-
duce hypokalemia, or directly prolong QT interval
may also potentiate this effect [7].
In the first case, QT prolongation was likely
associated with amiodarone, domperidone and ven-
lafaxine. Amiodarone is thought to generate ven-
tricular arrhythmias by prolonging the duration of
the ventricular action potential, thereby increasing
refractoriness even at therapeutic concentrations
[5]. However, the frequency of TdP generation with
amiodarone administration is remarkably low. It is
thought that the rarity of TdP with this drug, com-
pared to other class III antiarrhythmic drugs, may
be due to concurrent blockade of the L-type calcium
Figure 2. Electrocardiogram demonstrating a short-long-short sequence followed by an ‘R on T’ phenomenon
(arrow) initiating torsades de pointes. Note long QT interval preceding the initiation of the arrhythmia.
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channels, lack of reverse use dependence, and less
QT dispersion [8]. Oral domperidone, a prokinetic
agent, has been suggested as a drug that may cause
TdP [9]. However, though it has been shown to
prolong the QT interval by about 14 ms in infants
[10], a documented case of domperidone causing
TdP has not been reported. Venlafaxine, a selec-
tive serotonine/norepinephrine reuptake inhibitor,
was shown to cause QRS widening and ventricular
tachycardia by blocking the fast inward sodium cur-
rent (INa) in a concentration-dependent manner.
Although a dose-dependent relationship between
venlafaxine ingestion and prolonged QTc has also
been demonstrated [11], to our knowledge, venla-
faxine has not been reported as a cause of TdP. Each
of the aforementioned drugs is known to individu-
ally prolong QT interval. So, the role of each drug
in the presented cases remains speculative. It
seems likely that the combination of these drugs in
the setting of electrolyte disturbances ultimately led
to the prolongation of the QT interval and TdP in
the present case.
Figure 3. Case 2: electrocardiogram at admission (A) with QTc 720 ms and at discharge (B) with QTc 410 ms.
With regards to the second case, QT prolon-
gation was probably associated with citalopram and
quetiapine. A link between citalopram ingestion and
ECG alterations has been well established. Sever-
al reports, including one by our group, indicate that
these ECG changes include QTc prolongation [12],
TdP [13], widening of the QRS complex and junc-
tional rhythm with sinus arrest and/or atrioventricu-
lar dissociation [12]. Meanwhile, quetiapine, a new
generation antipsychotic drug, was shown by Har-
rigan et al. [2] to prolong the QT interval by 14.5 ±
± 5.0 ms. But until now, no cases of quetiapine-in-
duced TdP have been reported. Nonetheless, the
potential harm of polypsychotherapy has been de-
monstrated by one study [1] that showed that, com-
pared to patients on monotherapy, polytherapy pa-
tients treated with an antipsychotic with an additional
antidepressant and/or lithium had a significantly
increased mean QT interval.
The hypokalemic status of both of our patients
was likely induced by the use of diuretics. Notably,
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diuretics [14] is dose-dependent, and the severity
is accentuated with the combination of diuretics,
especially in the presence of a potent diuretic such
as metalozone [3]. The principle physiological
changes that can lead to arrhythmias in the setting
of hypokalemia are the increase in length and re-
fractory period of the action potential, automaticity
enhancement, and the decrease in myocardial con-
ductivity. These effects can lead to prolongation of
the QT-U interval, premature ventricular beats,
ventricular tachycardia and fibrillation [3, 15].
Another potential cause of hypokalemia in the
second case relates to the patient’s chronic alcohol
abuse. In fact, hypokalemia has commonly been
reported as an electrolyte abnormality observed in
chronic alcoholics, partly due to inappropriate ka-
liuresis as a result of co-existent hypomagnesae-
mia [16]. Moreover, acute alcohol withdrawal, as
seen in this case, has been reported to provoke in-
creased QT variability and repolarization lability,
which may elevate the risk for serious cardiac ar-
rhythmias [17].
Conclusions
These cases highlight the fact that though tor-
sades de pointes is an uncommon arrhythmia, the
combination of multiple factors known to prolong
QT interval may allow this life-threatening arrhyth-
mia to become manifest. While certain drugs direct-
ly cause prolongation of the QT interval, others
cause electrolyte disturbances that indirectly affect
QT duration. When these drugs are combined in
a patient with certain risk factors for QT prolonga-
tion, the result can be disastrous. It is of the utmost
importance that medical therapy be administered
prudently in order to minimize potentially deadly
risks.
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